These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 33651349)

  • 1. Mutational Analysis in Urinary Cell-Free DNA: KRAS in Colorectal Cancer.
    Molinari C; Chiadini E
    Methods Mol Biol; 2021; 2292():23-33. PubMed ID: 33651349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Cell-Free DNA Integrity Analysis.
    Casadio V; Salvi S
    Methods Mol Biol; 2021; 2292():17-22. PubMed ID: 33651348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
    Yu H; Han L; Yuan J; Sun Y
    Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
    Luo Y; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
    Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
    PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of
    Fujii T; Barzi A; Sartore-Bianchi A; Cassingena A; Siravegna G; Karp DD; Piha-Paul SA; Subbiah V; Tsimberidou AM; Huang HJ; Veronese S; Di Nicolantonio F; Pingle S; Vibat CRT; Hancock S; Berz D; Melnikova VO; Erlander MG; Luthra R; Kopetz ES; Meric-Bernstam F; Siena S; Lenz HJ; Bardelli A; Janku F
    Clin Cancer Res; 2017 Jul; 23(14):3657-3666. PubMed ID: 28096270
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
    Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
    Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
    Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
    Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.
    Yamada T; Iwai T; Takahashi G; Kan H; Koizumi M; Matsuda A; Shinji S; Yamagishi A; Yokoyama Y; Tatsuguchi A; Kawagoe T; Kitano S; Nakayama M; Matsumoto S; Uchida E
    Cancer Sci; 2016 Jul; 107(7):936-43. PubMed ID: 27116474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples.
    Vivancos A; Aranda E; Benavides M; Élez E; Gómez-España MA; Toledano M; Alvarez M; Parrado MRC; García-Barberán V; Diaz-Rubio E
    Sci Rep; 2019 Jun; 9(1):8976. PubMed ID: 31222012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
    Siena S; Sartore-Bianchi A; Garcia-Carbonero R; Karthaus M; Smith D; Tabernero J; Van Cutsem E; Guan X; Boedigheimer M; Ang A; Twomey B; Bach BA; Jung AS; Bardelli A
    Ann Oncol; 2018 Jan; 29(1):119-126. PubMed ID: 28945848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC.
    Xie F; Li P; Gong J; Tan H; Ma J
    Clin Transl Oncol; 2018 May; 20(5):591-598. PubMed ID: 28956302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    Yamada T; Matsuda A; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Koizumi M; Shinji S; Yokoyama Y; Ohta R; Yoshida H
    Int J Clin Oncol; 2020 Aug; 25(8):1523-1532. PubMed ID: 32394048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
    Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N
    Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer.
    Li J; Gan S; Blair A; Min K; Rehage T; Hoeppner C; Halait H; Brophy VH
    Arch Pathol Lab Med; 2019 Feb; 143(2):183-189. PubMed ID: 30088781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.